Skip header and navigation

Refine By

9 records – page 1 of 1.

Abnormal diurnal rhythm of urine output following renal transplantation: the impact of blood pressure and diuretics.

https://arctichealth.org/en/permalink/ahliterature139130
Source
Transplant Proc. 2010 Nov;42(9):3529-36
Publication Type
Article
Date
Nov-2010
Author
K. Alstrup
C. Graugaard-Jensen
S. Rittig
K A Jørgensen
Author Affiliation
Department of Nephrology, Aarhus University Hospital, Skejby, Denmark. karenalstrup@dadlnet.dk
Source
Transplant Proc. 2010 Nov;42(9):3529-36
Date
Nov-2010
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antihypertensive Agents - therapeutic use
Blood Pressure - drug effects
Case-Control Studies
Chi-Square Distribution
Circadian Rhythm
Denmark
Diuretics - therapeutic use
Drinking
Female
Humans
Kidney Transplantation - adverse effects
Male
Middle Aged
Osmolar Concentration
Polyuria - drug therapy - etiology - physiopathology
Prevalence
Time Factors
Treatment Outcome
Urination - drug effects
Urodynamics - drug effects
Young Adult
Abstract
Nocturnal polyuria is the excretion at night of an excessive volume of urine. A major problem following renal transplantation is an abnormal diurnal rhythmicity in urine output. The purpose of this study was to elucidate the prevalence of nocturnal polyuria among renal transplant recipients in the early period after transplantation as well as at least 1 year after transplantation. We aimed to explore possible pathophysiological mechanisms behind nocturnal polyuria in this group of patients, focusing on the impact of blood pressure and medication.
Seventeen recently transplanted patients 17 late transplant recipients, and 17 healthy controls were included in the study. Voiding habits were assessed by completion of a frequency-volume chart recording all fluid intakes and voiding. A concomitant 24-hour blood pressure profile was obtained in all.
Renal transplant recipients had a high prevalence of nocturnal polyuria (74%) and a disturbed blood pressure profile with a lack of appropriate nocturnal dipping (P
Notes
Comment In: J Urol. 2012 Mar;187(3):96422325519
PubMed ID
21094810 View in PubMed
Less detail

[Effect of naftusia mineral water at various temperatures on urination in rats]

https://arctichealth.org/en/permalink/ahliterature75242
Source
Vopr Kurortol Fizioter Lech Fiz Kult. 1984 Jul-Aug;(4):45-7
Publication Type
Article

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.

https://arctichealth.org/en/permalink/ahliterature210768
Source
CMAJ. 1996 Nov 1;155(9):1251-9
Publication Type
Article
Date
Nov-1-1996
Author
J C Nickel
Y. Fradet
R C Boake
P J Pommerville
J P Perreault
S K Afridi
M M Elhilali
Author Affiliation
Queen's University, Kingston, Ont.
Source
CMAJ. 1996 Nov 1;155(9):1251-9
Date
Nov-1-1996
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Canada
Double-Blind Method
Enzyme Inhibitors - adverse effects - therapeutic use
Finasteride - adverse effects - therapeutic use
Humans
Male
Middle Aged
Prospective Studies
Prostatic Hyperplasia - drug therapy
Safety
Urination - drug effects
Abstract
To evaluate the efficacy and safety of 2 years' treatment of moderate benign prostatic hyperplasia (BPH) with finasteride.
Double-blind, parallel-group, placebo-controlled, multicentre, prospective randomized study.
Outpatient care in 28 centres across Canada.
Men aged 45 to 80, in good health, with moderate BPH and no evidence of prostate cancer. A total of 613 men were entered into the study; 472 completed the 2 years of treatment.
After 1 month of receiving a placebo (run-in period), patients were given either finasteride (5 mg/d) or a placebo for 2 years.
changes from baseline in BPH symptom scores, maximum urinary flow rates and prostate volume.
onset, course and resolution of all adverse events during the treatment period.
In the efficacy analyses the mean BPH symptom scores decreased 2.1 points (from 15.8 to 13.7) in the finasteride group, as compared with a decrease of 0.7 points (from 16.6 to 15.9) in the placebo group (P
Notes
Cites: J Biol Chem. 1968 Apr 25;243(8):2012-214384673
Cites: N Engl J Med. 1992 Oct 22;327(17):1185-911383816
Cites: Eur Urol. 1992;22(4):271-71283370
Cites: J Urol. 1993 Aug;150(2 Pt 1):351-87686980
Cites: Arch Intern Med. 1994 Jan 10;154(1):83-87505563
Cites: J Urol. 1989 Feb;141(2):243-72643719
Cites: Urology. 1994 Mar;43(3):284-92; discussion 292-47510911
Cites: N Engl J Med. 1995 Jan 12;332(2):75-97527493
Cites: J Urol. 1996 Feb;155(2):595-6008558668
Cites: Urology. 1996 Mar;47(3):335-428633398
Cites: Br J Urol. 1973 Dec;45(6):631-454130099
Cites: N Engl J Med. 1974 Oct 31;291(18):944-94413434
Cites: Fed Proc. 1986 Oct;45(11):2609-142428671
Comment In: CMAJ. 1997 Apr 1;156(7):978-99099163
PubMed ID
8911291 View in PubMed
Less detail

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.

https://arctichealth.org/en/permalink/ahliterature192293
Source
Urology. 2001 Dec;58(6):953-9
Publication Type
Article
Date
Dec-2001
Author
C G Roehrborn
Author Affiliation
Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.
Source
Urology. 2001 Dec;58(6):953-9
Date
Dec-2001
Language
English
Publication Type
Article
Keywords
Adrenergic alpha-Antagonists - administration & dosage - adverse effects
Aged
Aged, 80 and over
Antihypertensive Agents - administration & dosage - adverse effects
Canada
Double-Blind Method
Drug Administration Schedule
Humans
Hypertension - complications - drug therapy
Male
Middle Aged
Prostatic Hyperplasia - complications - drug therapy
Quality of Life
Quinazolines - administration & dosage - adverse effects
United States
Urination - drug effects - physiology
Urination Disorders - drug therapy - etiology
Abstract
To assess the efficacy and safety, and determine the optimal dosage, of a once-daily (OD) formulation of the clinically uroselective alpha(1)-blocker, alfuzosin, in patients with lower urinary tract symptoms and symptomatic benign prostatic hyperplasia.
Five hundred thirty-six patients were randomized to receive alfuzosin (10 mg OD or 15 mg OD), without initial dose titration, or placebo in a 3-month double-blind trial conducted in North America. The primary efficacy criteria were improvement in symptoms (International Prostate Symptom Score) and peak urinary flow rate.
Alfuzosin was significantly more effective than placebo in improving the symptoms and peak urinary flow rate from the first follow-up visit (day 28). The mean change in the International Prostate Symptom Score from baseline at endpoint was -3.6 and -3.4 with alfuzosin 10 mg and 15 mg, respectively, compared with -1.6 with placebo (alfuzosin 10 mg versus placebo, P = 0.001; alfuzosin 15 mg versus placebo, P = 0.004). The median increase in the peak urinary flow rate was +1.1 mL/s and +1.0 mL/s with alfuzosin 10 mg and 15 mg, respectively, compared with 0.0 mL/s with placebo (P = 0.0006 versus placebo for both dose groups). The patients' quality of life also significantly improved with both alfuzosin doses. Overall, alfuzosin at both doses was well tolerated. The incidence of orthostatic hypotension as determined by systematic blood pressure measurements with both doses of alfuzosin was similar to placebo. No clinically relevant ejaculation disorders were observed with alfuzosin.
Alfuzosin 10 mg OD, administered without dose titration, provides effective relief from the symptoms of benign prostatic hyperplasia with no additional benefit from a 15-mg dose. It is well tolerated from a cardiovascular viewpoint and is not associated with abnormal ejaculation.
PubMed ID
11744466 View in PubMed
Less detail

Ethanol decreases nocturnal plasma levels of atrial natriuretic peptide (ANP 99-126) but not the N-terminal fragment of pro-atrial natriuretic peptide (ANP 1-98) in man.

https://arctichealth.org/en/permalink/ahliterature11594
Source
Clin Sci (Lond). 1994 Mar;86(3):285-90
Publication Type
Article
Date
Mar-1994
Author
A C Ekman
O. Vakkuri
O. Vuolteenaho
J. Leppäluoto
Author Affiliation
Department of Physiology, University of Oulu, Finland.
Source
Clin Sci (Lond). 1994 Mar;86(3):285-90
Date
Mar-1994
Language
English
Publication Type
Article
Keywords
Adult
Atrial Natriuretic Factor - blood
Comparative Study
Dose-Response Relationship, Drug
Double-Blind Method
Ethanol - pharmacology
Female
Humans
Male
Osmolar Concentration
Peptide Fragments - blood
Protein Precursors - blood
Research Support, Non-U.S. Gov't
Sodium - blood
Time Factors
Urination - drug effects
Water-Electrolyte Balance - drug effects
Abstract
1. The aim of this study was to elucidate the role of atrial natriuretic peptides in the regulation of water and electrolyte balance after alcohol intake. To this end we measured the plasma concentrations of ethanol, atrial natriuretic peptide 99-126 and the N-terminal fragment of pro-atrial natriuretic peptide (atrial natriuretic peptide 1-98), serum osmolality and serum sodium concentration, and urine output, urine osmolality and urinary sodium excretion for 12 h after administration of ethanol (0, 0.5 and 1.0 g body weight/kg) and placebo drinks to nine healthy subjects according to a double-blind cross-over design. 2. Intake of ethanol (at 19.00-19.45 hours) inhibited the nocturnal increase in the plasma atrial natriuretic peptide 99-126 level dose-dependently (P
PubMed ID
8156739 View in PubMed
Less detail

Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.

https://arctichealth.org/en/permalink/ahliterature225181
Source
Eur Urol. 1992;22(4):271-7
Publication Type
Article
Date
1992
Author
H O Beisland
B. Binkowitz
E. Brekkan
P. Ekman
M. Kontturi
T. Lehtonen
P. Lundmo
F. Pappas
E. Round
D. Shapiro
Author Affiliation
Aker University Hospital, Oslo, Norway.
Source
Eur Urol. 1992;22(4):271-7
Date
1992
Language
English
Publication Type
Article
Keywords
5-alpha Reductase Inhibitors
Adult
Aged
Aged, 80 and over
Androstenes - therapeutic use
Azasteroids - therapeutic use
Dihydrotestosterone - metabolism
Double-Blind Method
Finasteride
Follow-Up Studies
Humans
Male
Middle Aged
Osteocalcin - drug effects
Prostate-Specific Antigen - drug effects
Prostatic Hyperplasia - drug therapy - metabolism - physiopathology
Scandinavia
Testosterone - metabolism
Urination - drug effects
Abstract
The effects of finasteride, a potent 5 alpha-reductase inhibitor, were assessed in patients with benign prostatic hyperplasia. Patients were treated with finasteride or placebo for 24 weeks in a double-blind multicenter study followed by a 12-month open-extension period. After 24 weeks, finasteride-treated patients, when compared to placebo-treated patients, showed a significant reduction in prostate volume (22.5% median decrease) and prostate significant antigen (32.4% median decrease), a significant increase in maximum urinary flow (1.6 ml/s mean increase from baseline) and a significant improvement in their obstructive symptom scores (two-point decrease from baseline). Finasteride was well tolerated, and the improvements in prostate volume, maximum urinary flow rate and obstructive symptom scores observed in the controlled study were maintained throughout the extension study.
PubMed ID
1283370 View in PubMed
Less detail

[The classification of weakly mineralized therapeutic waters by the biological response of bile secretion and urination functions using multivariate assessment]

https://arctichealth.org/en/permalink/ahliterature72919
Source
Lik Sprava. 1996 Mar-Apr;(3-4):65-8
Publication Type
Article
Author
B A Lobasiuk
N A Alekseenko
K D Babov
Source
Lik Sprava. 1996 Mar-Apr;(3-4):65-8
Language
Russian
Publication Type
Article
Keywords
Animals
Bile - chemistry - drug effects - secretion
Discriminant Analysis
English Abstract
Female
Mineral Waters - classification - statistics & numerical data - therapeutic use
Multivariate Analysis
Rats
Rats, Wistar
Ukraine
Urinalysis
Urination - drug effects
Abstract
A scheme is proposed for the evaluation of the efficacy of the effect of those kinds of water containing little of mineral natural substances and having medicinal value, on the functions of bile secretion and urination. Using discriminant and component analyses, there has been formed a pragmatic classification of under-mineralized medicinal waters of Ukraine to be introduced into widespread use in practical public health care.
PubMed ID
9035886 View in PubMed
Less detail

[The use of ProstaDoz in patients with chronic prostatitis. Results ofa multicenter nonrandomized clinical study].

https://arctichealth.org/en/permalink/ahliterature104676
Source
Urologiia. 2013 Nov-Dec;(6):67-70, 72
Publication Type
Article
Author
A A Kamalov
I A Aboian
M È Sitdykova
A Iu Tsukanova
O V Teodorovich
V L Medvedev
B K Komiakov
V N Zhuravlev
A I Novikov
A A Erkovich
D A Okhobotov
V K Karpov
A Iu Zubkov
Source
Urologiia. 2013 Nov-Dec;(6):67-70, 72
Language
Russian
Publication Type
Article
Keywords
Adult
Chronic Disease
Humans
Male
Middle Aged
Plant Preparations - administration & dosage
Prostatitis - drug therapy - pathology - physiopathology
Quality of Life
Russia
Time Factors
Urination - drug effects
Abstract
The main purpose of the study was to determine the effectiveness of a multicomponent dietary supplement ProstaDoz in patients with chronic prostatitis. The study included 50 men with clinical symptoms of a chronic prostatitis, which were observed in 9 clinical centers in different regions of Russia. All patients have received 2 capsules of ProstaDoz twice a day for 1 month, followed by dynamic observation for 4 weeks. Symptomatic improvement was achieved in 46 (92%) patients. Evaluation of effects of ProstaDoz on various groups of symptoms has revealed that it reduces pain, promotes urination normalization and improvement of quality of life. These effects were maintained during all follow-up period.
PubMed ID
24649768 View in PubMed
Less detail

Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies.

https://arctichealth.org/en/permalink/ahliterature209984
Source
Eur Urol. 1997;32(1):39-46
Publication Type
Article
Date
1997
Author
P. Abrams
Author Affiliation
Bristol Urological Institute, Southmead General Hospital, Westbury-on-Trym, UK.
Source
Eur Urol. 1997;32(1):39-46
Date
1997
Language
English
Publication Type
Article
Keywords
Adrenergic alpha-Antagonists - administration & dosage - therapeutic use
Denmark
Double-Blind Method
Doxazosin - administration & dosage - therapeutic use
Great Britain
Humans
Hypertension - drug therapy
Male
Netherlands
Prostatic Hyperplasia - drug therapy
Urinary Bladder Neck Obstruction - drug therapy
Urination - drug effects
Urodynamics - drug effects
Abstract
Urodynamic investigations provide an objective, quantitative evaluation of urinary function in patients with benign prostatic obstruction (BPO). The effects of doxazosin, a selective alpha 1-adrenoceptor antagonist, on urodynamic measurements were investigated in three double-blind, placebo-controlled clinical studies of the treatment of BPO.
302 normotensive and mildly hypertensive men with BPO were evaluated. Patients were randomized to receive doxazosin (1-4 mg o.d.) or placebo for 4-29 weeks.
Doxazosin significantly improved free urinary flow rates compared with placebo. Urodynamic studies confirmed that doxazosin was effective in improving urinary flow, and also showed a reduction in detrusor pressure, resulting in decreased voiding time and increased voided volume. Analysis of pressure-flow data demonstrated a significant reduction in a measure of urethral resistance in doxazosin-treated patients.
These results indicate that doxazosin is an important treatment option for patients with troublesome lower urinary tract symptoms and BPO.
PubMed ID
9266230 View in PubMed
Less detail

9 records – page 1 of 1.